Literature DB >> 4043133

Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation.

R von Kries, H Stannigel, U Göbel.   

Abstract

In ten newborns with severe alteration of the coagulation system due to DIC, AT III concentrate was infused continuously after prior activation with heparin. The rise in AT III activity showed a great variability among the infants and for one child during the course of the therapy. The mean rise of AT III activity by 40 U/kg per day heparin was 8.7%. If AT III concentrate (40 U/kg per day) was activated with 200 U/kg per day heparin, excessive anticoagulation effect was only observed in one child. In four children who had failed to respond to prior heparin therapy, improvement of the coagulation status was achieved within 2 days.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043133     DOI: 10.1007/bf00451912

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  10 in total

1.  Hypercoagulability in premature infants with special reference to the respiratory distress syndrome and hemorrhage. II. The effect of heparin.

Authors:  M Markarian; L O Lubchenco; E Rosenblüt; F Fernandez; D Lang; J J Jackson; A E Bannon; A Lindley; J H Githens; R Martorell
Journal:  Biol Neonate       Date:  1971

2.  Activity of antithrombin III and effect of heparin on coagulation in shock.

Authors:  B Blauhut; S Necek; H Kramar; H Vinazzer; H Bergmann
Journal:  Thromb Res       Date:  1980-09-15       Impact factor: 3.944

3.  [Substitution therapy using antithrombin III concentrate].

Authors:  E Thaler; K Lechner
Journal:  Dtsch Med Wochenschr       Date:  1982-01-29       Impact factor: 0.628

4.  Substitution therapy with an antithrombin III concentrate in shock and DIC.

Authors:  B Blauhut; S Necek; H Vinazzer; H Bergmann
Journal:  Thromb Res       Date:  1982-08-01       Impact factor: 3.944

5.  Antithrombin in infancy and childhood.

Authors:  A Catrine; T Nilsson
Journal:  Acta Paediatr Scand       Date:  1975-07

6.  Etiopathology and classification of acquired coagulation disorders in the newborn infant.

Authors:  U Göbel; H von Voss; C Petrich; H Jürgens; A Oliven
Journal:  Klin Wochenschr       Date:  1979-01-15

7.  Plasma elimination of antithrombin III (heparin cofactor activity) is accelerated in term newborn infants.

Authors:  B Schmidt; U Wais; W Pringsheim; W Künzer
Journal:  Eur J Pediatr       Date:  1984-02       Impact factor: 3.183

8.  Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation.

Authors:  U Göbel; H von Voss; H Jürgens; C Petrich; R Pothmann; I Sprock; P Lemburg
Journal:  Eur J Pediatr       Date:  1980       Impact factor: 3.183

9.  Anticoagulant therapy by continuous heparinization in newborn and older infants.

Authors:  M M McDonald; W E Hathaway
Journal:  J Pediatr       Date:  1982-09       Impact factor: 4.406

10.  Antithrombin-III transfusion in disseminated intravascular coagulation.

Authors:  H G Schipper; C S Jenkins; L H Kahlé; J W ten Cate
Journal:  Lancet       Date:  1978-04-22       Impact factor: 79.321

  10 in total
  5 in total

Review 1.  Disseminated intravascular coagulation: diagnosis and management.

Authors:  K L Saving
Journal:  Indian J Pediatr       Date:  1987 May-Jun       Impact factor: 1.967

2.  Recombinant soluble human thrombomodulin (thrombomodulin alfa) in the treatment of neonatal disseminated intravascular coagulation.

Authors:  Akira Shirahata; Jun Mimuro; Hoyu Takahashi; Isao Kitajima; Hajime Tsuji; Yutaka Eguchi; Tadashi Matsushita; Masahiro Kajiki; Goichi Honda; Yoichi Sakata
Journal:  Eur J Pediatr       Date:  2013-09-05       Impact factor: 3.183

3.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

4.  Antithrombin concentrate use in children: a multicenter cohort study.

Authors:  Trisha E Wong; Yuan-Shung Huang; Jason Weiser; Thomas V Brogan; Samir S Shah; Char M Witmer
Journal:  J Pediatr       Date:  2013-08-06       Impact factor: 4.406

5.  Antithrombin III (AT) and recombinant tissue plasminogen activator (R-TPA) used singly and in combination versus supportive care for treatment of endotoxin-induced disseminated intravascular coagulation (DIC) in the neonatal pig.

Authors:  Rachel Davis-Jackson; Hernan Correa; Ronald Horswell; Halina Sadowska-Krowicka; Kathleen McDonough; Chittaranjan Debata; Renee' Gardner; Duna Penn
Journal:  Thromb J       Date:  2006-05-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.